Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10032800 | 0.87 | CA2 (0.53) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL1922788 | 0.87 | CA2 (0.53) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL10032797 | 0.84 | CA2 (0.54) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL14470792 | 0.84 | ALDH1A1 (0.65) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL378537 | 0.84 | ALDH1A1 (0.65) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL6943821 | 0.83 | CA2 (0.56) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL18395904 | 0.83 | CA2 (0.56) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL461346 | 0.83 | CA2 (0.56) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL6575404 | 0.83 | CA2 (0.56) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL18395905 | 0.81 | CA2 (0.54) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124793-B2 | Derivatives of ethylene methanedisulfonate as cancer chemotherapeutic agents | CRONYN MARSHALL W (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | CRONYN MARSHALL W | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | MGMT, ETV6, EI24 | CA2 3240/4885ALDH1A1 2643/4885TMEM97 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.